���重受体激动剂的分子设计 — Complete Guide

By Editorial Desk · published 2025-07-14 · last reviewed 2025-09-02 · Faq

peptide agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

Molecular Identity and Receptor Targets

Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.

Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.

Retatrutide at a glance

瑞他鲁肽药理机制

该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。

临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。

瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。

Related pages on this site

• Technical checklist
• Regional casebook
• Comprehensive collection
• Modern primer
• Standard report
• Scalable reference
• Measured index
• Optimized trends

Discovery and Triple Receptor Pharmacology

Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.

Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.

Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.

Trial Endpoints and Interpretation

Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.

Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.

Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.

Further detail

Bromine(I) fluorosulfonate is an inorganic compound of bromine, sulfur, fluorine, and oxygen with the chemical formula BrSO3F. This is a monovalent compound of bromine from the group of fluorosulfonates.

==== Natural resources ==== Initially, some mining executives feared that Castillo may nationalize mining, as he alluded during his electoral campaign. However, as of late, the Castillo Administration has toned down its rhetoric and showed greater willingness to work with private companies. Castillo has pledged to raise taxes on mining companies, and to make sure that projects are "socially profitable" for local mining communities. Prime Minister Guido Bellido has stated that he welcomes investment, as long as it means the development of the population. Later, the then prime minister stated that the energy sector should be under government control, while using the Camisea Gas Project as an example. In response, Economic Minister Pedro Francke ruled out expropriating the Camisea gas field. Francke also claimed that Bellido's call for government control of the energy sector was actually referring to state participation in the construction of a proposed natural gas pipeline, the Gran Gasoducto del Sur. However, PM Bellido later urged for the contract with the Camisea gas field to be renegotiated, threatening to nationalize the gas field if higher taxes aren't paid. The Prime Minister has also stated that strategic resources cannot remain in private hands. The Minister of Justice, Aníbal Torres, has stated that he's in favor of renegotiating the contract with Camisea, "like almost all the other ministers." However, Torres rejected the possibility of unilateral nationalization, and said that there were no talks about nationalization within the cabinet.

SRM has been used to identify the proteins encoded by wild-type and mutant genes (mutant proteins) and quantify their absolute copy numbers in tumors and biological fluids, thus answering the basic questions about the absolute copy number of proteins in a single cell, which will be essential in digital modelling of mammalian cells and human body, and the relative levels of genetically abnormal proteins in tumors, and proving useful for diagnostic applications. SRM has also been used as a method of triggering full product ion scans of peptides to either a) confirm the specificity of the SRM transition, or b) detect specific post-translational modifications which are below the limit of detection of standard MS analyses. In 2017, SRM has been developed to be a highly sensitive and reproducible mass spectrometry-based protein targeted detection platform (entitled "SAFE-SRM"), and it has been demonstrated that the SRM-based new pipeline has major advantages in clinical proteomics applications over traditional SRM pipelines, and it has demonstrated a dramatically improved diagnostic performance over that from antibody-based protein biomarker diagnostic methods, such as ELISA.

Sources: en.wikipedia.org

Supporting material

Purinergic receptors, also known as purinoceptors, are a family of plasma membrane molecules that are found in almost all mammalian tissues. Within the field of purinergic signalling, these receptors have been implicated in learning and memory, locomotor and feeding behavior, and sleep. More specifically, they are involved in several cellular functions, including proliferation and migration of neural stem cells, vascular reactivity, apoptosis and cytokine secretion. These functions have not been well characterized and the effect of the extracellular microenvironment on their function is also poorly understood. Geoffrey Burnstock originally separated purinoceptors into P1 adenosine receptors and P2 nucleotide (ATP, ADP) receptors. P2 receptors were later subdivided into P2X, P2Y, P2T, and P2Z receptors. Subclasses X and Y mediated vasoconstriction and vasodilation, respectively, in the smooth muscle of some arteries. They had been observed in blood vessels, smooth muscle, heart, hepatocytes, and parotid acinar cells. Subclass T was only observed in thrombocytes, platelets and megakaryocytes. Subclass Z required ~100 μM-ATP for activation, where the previous classes required <1 μM. They had been observed in mast cells and lymphocytes. In the early 1990s, purinoceptors were cloned and characterized, and the P2 subclasses were redefined. Now, P2 receptors are classified based on structure: P2X are ionotropic and P2Y are metabotropic. Appropriately, P2Z was reclassified as P2X7 and P2T was reclassified as P2Y1.

5 July Results of the 2024 United Kingdom general election: Sir Keir Starmer becomes the prime minister of the United Kingdom, following a landslide victory for Labour in the general election. The Conservatives are reduced to just 121 seats, the lowest number of MPs in their 190-year history. Among the high-profile losses are former Prime Minister Liz Truss, former cabinet minister Sir Jacob Rees-Mogg, Commons leader Penny Mordaunt, and Defence Secretary Grant Shapps. The Liberal Democrats, led by Sir Ed Davey, achieve their best ever result with 71 seats. The Green Party achieve their best ever result, quadrupling their number of seats to four. Reform UK gain their first seats in Parliament, which includes party leader Nigel Farage taking the constituency of Clacton. The SNP suffers heavy losses, going from 48 seats to just nine. Starmer ministry: Starmer appoints his first cabinet. Angela Rayner becomes Deputy Prime Minister Rachel Reeves becomes Chancellor of the Exchequer David Lammy becomes Foreign Secretary Yvette Cooper becomes Home Secretary John Healey becomes Defence Secretary 6 July Starmer holds his first press conference as prime minister, during which he confirms that the Rwanda deportation scheme is "dead and buried". Euro 2024: After finishing 1–1 at the end of extra time, England beat Switzerland 5–3 on penalties, taking them through to the semi-finals. Andy Murray's Wimbledon career comes to an end after Emma Raducanu withdraws from the mixed doubles.

Actin, alpha 1 Actinin, alpha 1 Adaptor-related protein complex 2, alpha 1 Aldehyde dehydrogenase 3 family, member A1 Aldehyde dehydrogenase 4 family, member A1 Aldehyde dehydrogenase 5 family, member A1 Aldehyde dehydrogenase 6 family, member A1 Aldehyde dehydrogenase 9 family, member A1 Aldehyde dehydrogenase 18 family, member A1 Aldo-keto reductase family 1, member A1 Alpha-1-microglobulin/bikunin precursor Apolipoprotein A1 and ApoA-1 Milano ATPase, H+ transporting, lysosomal V0 subunit a1 ATPase, Na+/K+ transporting, alpha 1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 1 BCL2-related protein A1 Butyrophilin, subfamily 1, member A1 Butyrophilin, subfamily 3, member A1 Capping protein (actin filament) muscle Z-line, alpha 1 Carboxypeptidase A1 Casein kinase 1, alpha 1 Casein kinase 2, alpha 1 Catenin (cadherin-associated protein), alpha 1 Centaurin, alpha 1 Cholinergic receptor, nicotinic, alpha 1 Coagulation factor XIII, A1 polypeptide collagen, type I, alpha 1 collagen, type II, alpha 1 Collagen, type III, alpha 1 Collagen, type IV, alpha 1 Collagen, type V, alpha 1 Collagen, type VI, alpha 1 Collagen, type VII, alpha 1 Collagen, type VIII, alpha 1 Collagen, type IX, alpha 1 Collagen, type X, alpha 1 Collagen, type XI, alpha 1 Collagen, type XII, alpha 1 Collagen, type XIII, alpha 1 Collagen, type XIV, alpha 1 Collagen, type XV, alpha 1 Collagen, type XVI, alpha 1 Collagen, type XVII, alpha 1 Collagen, type XVIII, alpha 1 Collagen, type XIX, alpha 1 Collagen, type XXV, alpha 1 Collagen, type XXVII, alpha 1 Crystallin, beta A1 Cyclic nucleotide-gated channel alpha 1 Cyclin A1 Cytochrome P450, family 1, member A1 Defensin, alpha 1 Dystrophin-associated protein A1 Ephrin A1 Eukaryotic translation elongation factor 1 alpha 1 Family with sequence similarity 13, member A1 Family with sequence similarity 19 (chemokine (C-C motif)-like), member A1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 Gap junction protein, alpha 1 GDNF family receptor alpha 1 Glutathione S-transferase A1 Glycine receptor, alpha 1 Heat shock protein 90kDa alpha (cytosolic), member A1 Hemoglobin, alpha 1 Heterogeneous nuclear ribonucleoprotein A1 Homeobox A1 Immunoglobulin heavy constant alpha 1 Importin alpha 1 Interferon, alpha 1 Interleukin 13 receptor, alpha 1 Karyopherin alpha 1 Laminin, alpha 1 Major histocompatibility complex, class II, DP alpha 1 Major histocompatibility complex, class II, DQ alpha 1 Myosin light chain A1, an actin-binding protein NADH dehydrogenase (ubiquinone), alpha 1 Nucleolar protein, member A1 PCDHA4 Phospholipase A1 Phosphorylase kinase, alpha 1 Plexin A1 Polymerase (DNA directed), alpha 1 Potassium large conductance calcium-activated channel, subfamily M, alpha 1 Proteasome (prosome, macropain) subunit, alpha 1 Protein kinase, AMP-activated, alpha 1 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 Protocadherin alpha 1 Pulmonary surfactant-associated protein A1 Pyruvate dehydrogenase (lipoamide) alpha 1 RNA binding motif protein, Y-linked, family 1, member A1 Replication protein A1 S100 calcium binding protein A1 Sec61 alpha 1 Serum amyloid A1 Solute carrier family 35 (CMP-sialic acid transporter), member A1 Spectrin, alpha 1 Sperm protein associated with the nucleus, X-linked, family member A1 Syntrophin, alpha 1 Transient receptor potential cation channel, member A1 UDP glucuronosyltransferase 1 family, polypeptide A1 Urea Transporter A1 a gene found in the maize encoding for the dihydroflavonol 4-reductase (reducing dihydroflavonols into flavan-4-ols) in the phlobaphene metabolic pathway proteins

Crick's view of the relationship between science and religion continued to play a role in his work as he made the transition from molecular biology research into theoretical neuroscience. Crick asked in 1998 "and if some of the Bible is manifestly wrong, why should any of the rest of it be accepted automatically? ... And what would be more important than to find our true place in the universe by removing one by one these unfortunate vestiges of earlier beliefs?" In 2003 he was one of 22 Nobel laureates who signed the Humanist Manifesto.

Sources: en.wikipedia.org

Supporting material

=== Roles in endocrine regulation === Decreases basal corticotropin level and blocks its release. Stimulates release of luteinizing hormone (LH). Stimulates release of somatoliberin and somatotrophin secretion and inhibits somatostatin secretion.

=== Early actions === The Japanese had already launched their morning search patrols, using some of the 50 aircraft stationed on Guam, and at 05:50 one of these, a Mitsubishi A6M Zero, found TF-58. After radioing his sighting of U.S. ships, the bomb-carrying Zero attacked picket destroyer Stockham but was shot down by the destroyer Yarnall. Alerted, the Japanese began launching their Guam-based aircraft for an attack. These were spotted on radar by U.S. ships. A group of thirty Grumman F6F Hellcats were dispatched from USS Belleau Wood to deal with the threat. The Hellcats arrived while aircraft were still launching from Orote Field. Minutes later, additional radar contacts were seen, which were later discovered to be the additional forces being sent north from the other islands. A battle broke out in which 35 Japanese aircraft were shot down for the loss of a single Hellcat. It was a pattern that would be repeated throughout the day. At 09:57 large numbers of Japanese aircraft were picked up approaching the fleet. Mitscher said to Burke, "Get those fighters back from Guam." The call "Hey, Rube!" was sent out. The fleet held steady until 10:23, when Mitscher ordered TF 58 to turn into the wind on course east-southeast, and ordered all fighter aircraft aloft, deployed in several layers of CAP to await the Japanese. He then sent his bomber aircraft aloft to orbit open waters to the east rather than leaving them in a hangar deck full of aircraft vulnerable to a Japanese bomb attack.

== Further reading == Holmer, Marianne. Aquaculture in the Ecosystem. Dordrecht, Netherlands: Springer, 2008. Molyneaux, Paul. Swimming in Circles: Aquaculture and the End of Wild Oceans. New York: Thunder's Mouth Press, 2006. Stickney, Robert R. Aquaculture: An Introductory Text. Oxford, UK; Cambridge, MA: CABI Publishing, 2005. World Bank. Changing the Face of the Waters: The Promise and Challenge of Sustainable Aquaculture. Washington, DC: World Bank, 2007.

Sources: en.wikipedia.org

Frequently asked questions